Tempus AI, Inc. (TEM) Stock Analysis
Falling Knife setup
Healthcare · Health Information Services
Sell if holding. Engine safety override at $43.81: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Elevated put/call ratio: 1.37; Below-average business quality.
Tempus AI is a healthcare AI company providing intelligent diagnostics and data analytics through its platform connecting 700+ data pipelines at 5,000+ healthcare institution sites across oncology, cardiology, and neuropsychiatry. Revenue comes from Diagnostics (oncology and... Read more
Sell if holding. Engine safety override at $43.81: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Elevated put/call ratio: 1.37; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Score 5.6/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Tempus AI, Inc.
Latest news
- Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery — benzinga May 20, 2026 neutral
- Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts — benzinga May 14, 2026 positive
- Tempus AI Partners With Bristol Myers Squibb Over Leveraging AI, Multimodal Real-World Data, Data Science Techniques For — benzinga May 14, 2026 positive
- Ark Invest Again Sells AMD, This Time As Stock Hits 52-Week High While Snapping Up Tempus AI And Circle — benzinga May 11, 2026 positive
- HC Wainwright & Co. Maintains Buy on Tempus AI, Lowers Price Target to $64 — benzinga May 11, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 7.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -22.2%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $43.81: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Elevated put/call ratio: 1.37; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Prior stop was $41.84. Score 5.6/10, moderate confidence.
Take-profit target: $60.48 (+38.7% upside). Prior stop was $41.84. Stop-loss: $41.84.
Quality below floor (3.2 < 4.0); Value-trap signals (2/5): High leverage (D/E 2.1), Material insider selling (28 sells, 0.12% of cap).
Tempus AI, Inc. trades at a P/E of N/A (forward -323.4). TrendMatrix value score: 8.0/10. Verdict: Sell.
24 analysts cover TEM with a consensus score of 3.8/5. Average price target: $67.
What does Tempus AI, Inc. do?Tempus AI is a healthcare AI company providing intelligent diagnostics and data analytics through its platform...
Tempus AI is a healthcare AI company providing intelligent diagnostics and data analytics through its platform connecting 700+ data pipelines at 5,000+ healthcare institution sites across oncology, cardiology, and neuropsychiatry. Revenue comes from Diagnostics (oncology and hereditary testing at 74% of 2025 revenue) and Data & Applications lines.